Diagnosis of families with familial hypercholesterolaemia and/or Apo B‐100 defect by means of DNA analysis of LDL‐receptor gene mutations
- 8 March 2007
- journal article
- Published by Wiley in Journal of Inherited Metabolic Disease
- Vol. 30 (2) , 239-247
- https://doi.org/10.1007/s10545-007-0563-5
Abstract
Background: One major problem of using hypercholesterolaemia alone as a primary criterion for diagnosing familial hypercholesterolaemia (FH) is that 15–40% of relatives may be misdiagnosed because plasma lipid levels in FH heterozygotes overlap with those in the general population. Setting: General Hospital/University of Vienna, Department of Pediatrics, Outpatient lipid clinic. Methods: As a part of the MED-PED (make early diagnosis – prevent early death) project we are currently investigating children, adolescents and their relatives who are suspected to be affected with FH in our out-patient clinic for metabolic diseases using MED-PED inclusion criteria and confirming the diagnosis by means of DNA analysis. Patients: 263 patients with premature atherosclerosis and/or hypercholesterolaemia: 116 children (mean age 11.6 ± 4.1 years; 57 girls and 59 boys) and 147 adults (64 women, mean age 41.5 ± 13.7 years; 83 men, mean age 42.8 ± 10.8 years). Results: 119 patients with mutations have been detected; 56 children with either low density lipoprotein receptor (LDLR) and/or ApoB mutations (27 girls and 29 boys; mean total cholesterol (TC) 275 ± 71 mg/dl, triglycerides (TG) 101 ± 57 mg/dl, high-density lipoprotein cholesterol (HDL-C) 49 ± 12 mg/dl, low-density lipoprotein cholesterol (LDL-C) 198 ± 67 mg/dl) and one boy with a homozygous. LDLR mutation. A further 62 adults with LDLR and/or ApoB mutations were documented; 33 women (mean age 36.9 ± 11.1 years; mean TC 283 ± 76 mg/dl, TG 137 ± 78 mg/dl, HDL-C 55 ± 17 mg/dl, LDL-C 210 ± 67 mg/dl) and 29 men (mean age 45.0 ± 10.6 years; mean TC 301 ± 87 mg/dl, TG 163 ± 112 mg/dl, HDL-C 42 ± 12 mg/dl, LDL-C 233 ± 83 mg/dl). In 32 of these subjects (11 children (21%), 21 adults (42%)), serum lipid levels were lower than the diagnostic MED-PED limits adopted, so that they might have been misclassified without an additional DNA analysis. Conclusion: In our study, diagnosis of FH and related disorders (ApoB-100 defect) by means of conventional laboratory methods missed at least 21% in children and 42% in adults affected with LDLR and/or ApoB gene mutations. Genetic FH diagnosis provides a tool for specific diagnosis of mutation carrier status.Keywords
This publication has 40 references indexed in Scilit:
- Intrafamilial variability in the clinical expression of familial hypercholesterolemia: importance of risk factor determination for genetic counsellingClinical Genetics, 2008
- Diagnosing familial hypercholesterolaemia: the relevance of genetic testingEuropean Heart Journal, 2006
- A randomized, open-label, comparative study of simvastatin plus diet versus diet alone on angiographic retardation of coronary atherosclerosis in adult Japanese patients: Japanese utilization of simvastatin therapy (JUST) studyClinical Therapeutics, 2004
- Familial Hypercholesterolemia in the Finnish North KareliaArteriosclerosis, Thrombosis, and Vascular Biology, 1997
- Documented need for more effective diagnosis and treatment of familial hypercholesterolemia according to data from 502 heterozygotes in UtahThe American Journal of Cardiology, 1993
- Familial hypercholesterolemia in French-Canadians: Taking advantage of the presence of a “founder effect”The American Journal of Cardiology, 1993
- Diagnosing heterozygous familial hypercholesterolemia using new practical criteria validated by molecular geneticsPublished by Elsevier ,1993
- The familial hypercholesterolemia (FH)-North Karelia mutation of the low density lipoprotein receptor gene deletes seven nucleotides of exon 6 and is a common cause of FH in Finland.Journal of Clinical Investigation, 1992
- I. Familial hypercholesterolemia with “normal” cholesterol in obligate heterozygotesAmerican Journal of Medical Genetics, 1985
- NEONATAL DIAGNOSIS OF FAMILIAL TYPE-II HYPERLIPOPROTEINÆMIAThe Lancet, 1973